Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Glecaprevir/Pibrentasvir (G/P); Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Upper Limb Spasticity
Interventions: ABBV-950, BOTOX, Placebo for ABBV-950; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 9
States / cities: Carlsbad, California • Downey, California • Fresno, California + 6 more

Conditions: Healthy
Interventions: ABBV-CLS-7262, Placebo, Moxifloxacin 400mg; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Ulcerative Colitis (UC), Crohn's Disease
Interventions: Risankizumab, Cytochrome P450 (CYP) Substrates; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Coronado, California • DeLand, Florida • Margate, Florida + 1 more

Conditions: Generalized Anxiety Disorder (GAD), Healthy Participants
Interventions: ABBV-932, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions: RGX-314; Genetic
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 865 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more

Conditions: Psoriasis
Interventions: Placebo for Risankizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more

Conditions: Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma, Unresectable Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Veliparib; Other · Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Myeloid, Acute
Interventions: CC-90009, Venetoclax, Azacitidine, Gilteritinib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more

Conditions: Diffuse Large B Cell Lymphoma
Interventions: 18F-FluorApoTrace; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Interventions: Azacitidine, Decitabine, Venetoclax; Drug
Lead sponsor: Brian Jonas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Clovis, California • Los Angeles, California • Sacramento, California + 1 more

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Imaging Apoptosis for Lymphoma Treatment Response

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

About this AbbVie sponsor directory page